Circulating T cell profiles associate with enterotype signatures underlying hematological malignancy relapses. Cell Host & Microbe
Comparison of NK alloreactivity prediction models based on KIR-MHC interactions in haematopoietic stem cell transplantation. Frontiers in Immunology
Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation. Blood
High Predictive Value of the Soluble ZEBRA Antigen (Epstein-Barr Virus Trans-Activator Zta) in Transplant Patients with PTLD. Pathogens
Operational tolerance after hematopoietic stem cell transplantation is characterized by distinct transcriptional, phenotypic, and metabolic signatures. Science Translational Medicine. 2022.
Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy. Journal for ImmunoTherapy of Cancer.
Innate lymphoid cell recovery and occurrence of GvHD after hematopoietic stem cell transplantation. J Leukoc Biol.
Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD. Blood Advances.
“CRYOSTEM Biobank: A National Prospective, Standardized Collection to Better Characterize Allogeneic Hematopoietic Stem Cell Transplantation Complications”. Open Journal of Bioresources.
Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites. Nature Communications.
CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. Blood.
Current issues in chronic graft-versus-host disease. Blood.
Multiparameter single-cell profiling of human CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease. Blood.
Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease. Blood.
Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. Blood.
Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood.
Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol.